|中肽生化内容团队编辑2026年2月24日,联邦制药国际控股有限公司(联邦制药)与Novo Nordisk A/S(诺和诺德)联合发布GLP-1/GIP/GCG三靶点受体激动剂(三激动剂)UBT251中国II期临床研究的主要结果。UBT251 由联邦制药之全资附属公司——联邦生物科技(珠海横琴)有限公司(联邦生物)与诺和诺德根据 2025年3月签署许可协议共同开发。联邦生物负责中国内地(大陆)、...
Source Link|中肽生化内容团队编辑2026年2月24日,联邦制药国际控股有限公司(联邦制药)与Novo Nordisk A/S(诺和诺德)联合发布GLP-1/GIP/GCG三靶点受体激动剂(三激动剂)UBT251中国II期临床研究的主要结果。UBT251 由联邦制药之全资附属公司——联邦生物科技(珠海横琴)有限公司(联邦生物)与诺和诺德根据 2025年3月签署许可协议共同开发。联邦生物负责中国内地(大陆)、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.